Simon Turcotte
Overview
Explore the profile of Simon Turcotte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
3272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berry D, Moldoveanu D, Rajkumar S, Lajoie M, Lin T, Tchelougou D, et al.
Cell Rep
. 2025 Mar;
44(3):115365.
PMID: 40023845
Hotspot BRAF, hotspot NRAS, and NF1 loss-of-function mutations are found in approximately 50%, 25%, and 15% of cutaneous melanomas, respectively. Compared to mutant BRAF and NRAS, the role of NF1...
2.
Turcotte S, Donia M, Gastman B, Besser M, Brown R, Coukos G, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39837618
In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is...
3.
Elforaici M, Montagnon E, Romero F, Le W, Azzi F, Trudel D, et al.
Med Image Anal
. 2024 Oct;
99:103346.
PMID: 39423564
Colorectal liver metastases (CLM) affect almost half of all colon cancer patients and the response to systemic chemotherapy plays a crucial role in patient survival. While oncologists typically use tumor...
4.
Montagnon E, Cerny M, Hamilton V, Derennes T, Ilinca A, Elforaici M, et al.
PLoS One
. 2024 Sep;
19(9):e0307815.
PMID: 39259736
Objective: The purpose of this study was to determine and compare the performance of pre-treatment clinical risk score (CRS), radiomics models based on computed (CT), and their combination for predicting...
5.
Proteau S, Krossa I, Husser C, Gueguinou M, Sella F, Bille K, et al.
EMBO Mol Med
. 2024 Aug;
16(9):2262-2267.
PMID: 39164473
No abstract available.
6.
Tchelougou D, Malaquin N, B Cardin G, Desmul J, Turcotte S, Rodier F
Front Cell Dev Biol
. 2024 Jul;
12:1368711.
PMID: 38946802
Malignant Melanoma that resists immunotherapy remains the deadliest form of skin cancer owing to poor clinically lasting responses. Alternative like genotoxic or targeted chemotherapy trigger various cancer cell fates after...
7.
Goossens C, Tambay V, Raymond V, Rousseau L, Turcotte S, Bilodeau M
PLoS One
. 2024 Jun;
19(6):e0304405.
PMID: 38857235
The liver is a highly specialized organ involved in regulating systemic metabolism. Understanding metabolic reprogramming of liver disease is key in discovering clinical biomarkers, which relies on robust tissue biobanks....
8.
Lopes-Paciencia S, Bourdeau V, Rowell M, Amirimehr D, Guillon J, Kalegari P, et al.
Cell Rep
. 2024 Apr;
43(4):114044.
PMID: 38568812
We identify a senescence restriction point (SeRP) as a critical event for cells to commit to senescence. The SeRP integrates the intensity and duration of oncogenic stress, keeps a memory...
9.
Briere R, Emond M, Benhamed A, Blanchard P, Golbon B, Shellenberger J, et al.
Can J Surg
. 2024 Jan;
66(6 Suppl 1):S54-S136.
PMID: 38173057
No abstract available.
10.
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition
Proteau S, Krossa I, Husser C, Gueguinou M, Sella F, Bille K, et al.
EMBO Mol Med
. 2023 Nov;
15(12):e17719.
PMID: 37966164
Metastatic uveal melanomas are highly resistant to all existing treatments. To address this critical issue, we performed a kinome-wide CRISPR-Cas9 knockout screen, which revealed the LKB1-SIK2 module in restraining uveal...